News

Eisai Co., Ltd. announced that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and…
Read More...

Johnson & Johnsonannounced that the U.S. Food and Drug Administration (FDA) has approved EDURANT PED (rilpivirine) for the treatment of HIV-1 in combination with other…
Read More...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced it has signed an agreement to acquire the Genentech large-scale biologics…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and…
Read More...

Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved SPEVIGO (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP)…
Read More...

Bristol Myers Squibb announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased…
Read More...

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).…
Read More...

Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U.S. Food and…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for…
Read More...

Novartis announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The US$256 million investment will facilitate Novartis in deploying…
Read More...

Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains…
Read More...

Merck, known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union…
Read More...

Tierra Biosciences, the company behind the world’s first platform for predictive AI-guided cell-free technology enabling high-throughput on-demand custom protein synthesis, announced…
Read More...

Pearl Bio (a synthetic biology company backed by Khosla Ventures) announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the…
Read More...

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for the…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA…
Read More...

Johnson & Johnson announced it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology…
Read More...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company broke ground on a major expansion…
Read More...